Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Zimmer Biomet Holdings, Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $17.0B | |
|---|---|---|
| Revenue (ttm) | 8.5B | |
| Net income (ttm) | 806.7M | |
| EPS (ttm) | $4.12 | |
| Shares out | 190.7M | |
| P/E (trailing) | 23.4x | |
| P/E (forward) | 10.1x | |
| Dividend | $0.96 (1.00%) | |
| Volume | 1,814,544 | |
| Beta | 0.49 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $6.83B | $6.94B | $7.39B | $7.68B | $8.23B | +4.8% |
| Gross profit | $4.87B | $4.92B | $5.31B | $5.49B | $5.07B | +1.0% |
| Operating income | $860.3M | $696.3M | $1.28B | $1.29B | $1.10B | +6.3% |
| Net income | $401.6M | $231.4M | $1.02B | $903.8M | $705.1M | +15.1% |
| EPS (diluted) | $1.91 | $1.10 | $4.88 | $4.43 | $3.55 | +16.8% |
| EBITDA | $1.65B | $1.49B | $2.22B | $2.25B | $2.22B | +7.7% |
| R&D | $435.8M | $406.0M | $458.7M | $437.4M | $458.5M | +1.3% |
| SG&A | $2.84B | $2.76B | $2.84B | $2.93B | $3.26B | +3.5% |
Recent company headlines from major financial publishers.
Under the base case, Zimmer Biomet executes its commercial reorganization across three stages through 2027, stabilizing domestic knee and hip market share while ROSA robotics placements expand procedural volume. FY2026 reported revenue grows 4.43% to $8,596.2M, and FY2027 revenue reaches $8,904.5M. Operating margins trough at 13.0% in FY2026 before expanding to 14.0% in FY2027 and 16.0% by FY2030. Diluted EPS expands from $8.53 in FY2026 to $9.07 in FY2027, supported by share repurchases of up to $1.0B.
In the bull case, rapid ROSA surgical robotics placement drives accelerating market share gains in knees and shoulders, while international launches of first-to-world iodine-coated hips in Japan achieve rapid market conversion at 40% premiums. Salesforce specialization concludes ahead of schedule with negligible turnover. Revenue growth accelerates to 5.0% and operating margins reach 17.0%, propelling intrinsic value toward $185.55.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 6.4% | $131 | $136 | $141 | $147 | $153 |
| 6.9% | $122 | $125 | $129 | $133 | $138 |
| 7.4% | $114 | $116 | $120 | $123 | $127 |
| 7.9% | $107 | $109 | $112 | $115 | $118 |
| 8.4% | $101 | $103 | $105 | $108 | $110 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
